OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer

SIMPLE SUMMARY: Arginase 1 and 2 are drivers of multiple immunosuppressive mechanisms and tumour-specific metabolic adaptations. Pharmacological inhibition of extracellular ARG1 has shown antitumour efficacy in various syngeneic tumour models, however, the importance of ARG2 as a therapeutic target...

Descripción completa

Detalles Bibliográficos
Autores principales: Grzybowski, Marcin Mikołaj, Stańczak, Paulina Seweryna, Pomper, Paulina, Błaszczyk, Roman, Borek, Bartłomiej, Gzik, Anna, Nowicka, Julita, Jędrzejczak, Karol, Brzezińska, Joanna, Rejczak, Tomasz, Güner-Chalimoniuk, Nazan Cemre, Kikulska, Agnieszka, Mlącki, Michał, Pęczkowicz-Szyszka, Jolanta, Olczak, Jacek, Gołębiowski, Adam, Dzwonek, Karolina, Dobrzański, Paweł, Zasłona, Zbigniew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406419/
https://www.ncbi.nlm.nih.gov/pubmed/36010962
http://dx.doi.org/10.3390/cancers14163967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406419/
https://www.ncbi.nlm.nih.gov/pubmed/36010962
http://dx.doi.org/10.3390/cancers14163967

Ejemplares similares